NASDAQ:PPH VanEck Pharmaceutical ETF (PPH) Price, Holdings, & News $89.16 +0.28 (+0.32%) Closing price 04:00 PM EasternExtended Trading$89.16 0.00 (0.00%) As of 04:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisChartDividendHeadlinesHoldingsOptions ChainOwnershipRatingsTrendsBuy This Stock About VanEck Pharmaceutical ETF (NASDAQ:PPH) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get PPH alerts:Sign Up Key Stats Today's Range$88.50▼$89.2550-Day Range$82.58▼$89.6752-Week Range$77.67▼$99.51Volume341,173 shsAverage Volume397,807 shsMarket Capitalization$485.03 millionAssets Under Management$625.65 millionDividend Yield2.19%Net Expense Ratio0.36%Aggregate RatingModerate Buy ETF Overview The VanEck Pharmaceutical ETF (PPH) is an exchange-traded fund that is based on the MVIS US Listed Pharmaceutical 25 index, a market-cap-weighted index of 25 of the largest global pharmaceutical firms. PPH was launched on Feb 1, 2000 and is managed by VanEck. Read More VanEck Pharmaceutical ETF ExpensesTypePPHHealth Care ETFsEquity ETFsNASDAQ ETFsAll ETFsManagement Fee0.35%0.56%0.56%0.54%0.53%Other Expenses0.01%0.47%0.56%0.52%0.56%Total Expense0.36%0.75%0.76%0.73%0.73%Fee Waiver0.00%-0.67%-0.66%-0.50%-0.63%Net Expense0.36%0.60%0.63%0.63%0.60% Receive PPH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for VanEck Pharmaceutical ETF and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PPH ETF News HeadlinesJ&J rallies big pharma after earnings despite Trump’s latest tariff threatJuly 16, 2025 | msn.comPPH: Global Pharma Stocks Continue To Face Headwinds, Tariffs Front And CenterJuly 7, 2025 | seekingalpha.comI’d rather trade news like this than gamble on hypeReal traders are watching Nvidia’s next move—after U.S. approval to resume chip sales to China. This reversal just triggered a key alert in Tim Sykes’ system… and the setup looks strong.September 2 at 2:00 AM | Timothy Sykes (Ad)VanEck Vectors Pharmaceutical ETF declares quarterly distribution of $0.6069July 1, 2025 | msn.comGlobal pharma stocks down as Trump renews tariff threatJune 17, 2025 | msn.comPPH, Big Pharma Stocks Volatile on Trump Drug PricingMay 14, 2025 | finance.yahoo.comSee More Headlines PPH ETF - Frequently Asked Questions How have PPH shares performed this year? VanEck Pharmaceutical ETF's stock was trading at $86.28 at the beginning of 2025. Since then, PPH stock has increased by 3.3% and is now trading at $89.09. Who are VanEck Pharmaceutical ETF's major shareholders? VanEck Pharmaceutical ETF's top institutional shareholders include Clal Insurance Enterprises Holdings Ltd (5.97%), Avalon Trust Co (5.16%), J.Safra Asset Management Corp (4.77%) and JPMorgan Chase & Co. (4.70%). How do I buy shares of VanEck Pharmaceutical ETF? Shares of PPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of VanEck Pharmaceutical ETF own? Based on aggregate information from My MarketBeat watchlists, some other companies that VanEck Pharmaceutical ETF investors own include Waste Connections (WCN), iShares Micro-Cap ETF (IWC), The RMR Group (RMR), DiamondRock Hospitality (DRH), AU Optronics (AUOTY), American Water Works (AWK) and Triple Flag Precious Metals (TFPM). Fund Details IssuerVan Eck Fund NameVanEck Pharmaceutical ETF Tax ClassificationRegulated Investment Company Stock ExchangeNASDAQCurrent SymbolNASDAQ:PPH Inception Date12/20/2011 Fund ManagerHao-Hung Peter Liao, Guo Hua Jason Jin WebN/A Phone14089961010Fund Focus Asset ClassEquity BenchmarkMVIS US Listed Pharmaceutical 25 Index CategorySector FocusHealth Care Development LevelDeveloped Markets RegionGlobal Number of Holdings25 Fund Statistics Assets Under Management$625.65 million Average Daily Volume$357.67 thousand Discount/Premium-0.01% Administrator, Advisor and Custodian AdministratorVan Eck Associates Corporation AdvisorVan Eck Associates Corporation CustodianState Street Bank and Trust Company DistributorVan Eck Securities Corporation Transfer AgentState Street Bank and Trust Company TrusteeN/A Lead Market MakerIMC Options OptionableOptionable Options Volume153 Put Options153 Call Options3 Short Interest2,570,000 shs Miscellaneous Outstanding Shares5,440,000Beta0.72 Creation Unit50,000 Creation Fee$500.00 The 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Top 10 PPH HoldingsEli Lilly and Company (NYSE:LLY)Holding Weight: 16.70%Johnson & Johnson (NYSE:JNJ)Holding Weight: 11.60%Novartis AG ADRHolding Weight: 7.88%Merck & Co., Inc. (NYSE:MRK)Holding Weight: 6.28%Novo Nordisk A/S (NYSE:NVO)Holding Weight: 6.00%AbbVie (NYSE:ABBV)Holding Weight: 5.00%AstraZeneca (NASDAQ:AZN)Holding Weight: 4.99%Pfizer (NYSE:PFE)Holding Weight: 4.81%Sanofi (NASDAQ:SNY)Holding Weight: 4.66%McKesson (NYSE:MCK)Holding Weight: 4.50%Full Holdings DetailsPPH Sector ExposurePPH Industry Exposure This page (NASDAQ:PPH) was last updated on 9/2/2025 by MarketBeat.com Staff From Our PartnersMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredThe day and month stocks are most likely to crash nextGood News for Stocks 50-year Wall Street veteran, Marc Chaikin is stepping forward to share why history giv...Chaikin Analytics | SponsoredLeaked Gov’t Memo Reveals $100 Trillion DeadlineOnly Days Left to Claim Your Share of Trump's $100T Play Trump's economic blueprint is about to go live, an...Stansberry Research | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored2013 Bitcoin miner reveals his trading system (free)While everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding VanEck Pharmaceutical ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share VanEck Pharmaceutical ETF With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
